SPOTLIGHT: Will Rituxan be next MS breakthrough?


The cancer drug Rituxan cut multiple sclerosis lesions and relapses in a small clinical trial; its developers, Genentech and Biogen Idec, hope to establish its efficacy in larger trials. Report